[go: up one dir, main page]

MX2023003783A - Formulaciones farmaceuticas para tratar enfermedades mediadas por kdm1a. - Google Patents

Formulaciones farmaceuticas para tratar enfermedades mediadas por kdm1a.

Info

Publication number
MX2023003783A
MX2023003783A MX2023003783A MX2023003783A MX2023003783A MX 2023003783 A MX2023003783 A MX 2023003783A MX 2023003783 A MX2023003783 A MX 2023003783A MX 2023003783 A MX2023003783 A MX 2023003783A MX 2023003783 A MX2023003783 A MX 2023003783A
Authority
MX
Mexico
Prior art keywords
kdm1a
pharmaceutical formulations
treat diseases
diseases mediated
ropylamino
Prior art date
Application number
MX2023003783A
Other languages
English (en)
Inventor
Cassandra Celatka
Amy Tapper
Patricia Soulliac
Parag Ved
Namrata Vora
Original Assignee
Imago Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imago Biosciences Inc filed Critical Imago Biosciences Inc
Publication of MX2023003783A publication Critical patent/MX2023003783A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se provee una composición farmacéutica que comprende: N-((S)-5-((1R,2S)-2-(4-fluorofenil)ciclopropilamino)-1-(4-metilpi perazin-1-il)-1-oxopentan-2-il)-4-(1H-1,2,3-triazol-1-il)benzamid a (Compuesto A), o una sal farmacéuticamente aceptable de la misma, y por lo menos un estabilizante, preparaciones farmacéuticas de la misma, y métodos para el tratamiento de una enfermedad o trastorno asociado con la actividad de KDM1A.
MX2023003783A 2020-10-01 2021-10-01 Formulaciones farmaceuticas para tratar enfermedades mediadas por kdm1a. MX2023003783A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063086353P 2020-10-01 2020-10-01
PCT/US2021/053141 WO2022072811A1 (en) 2020-10-01 2021-10-01 Pharmaceutical formulations for treating diseases mediated by kdm1a

Publications (1)

Publication Number Publication Date
MX2023003783A true MX2023003783A (es) 2023-04-26

Family

ID=80951023

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003783A MX2023003783A (es) 2020-10-01 2021-10-01 Formulaciones farmaceuticas para tratar enfermedades mediadas por kdm1a.

Country Status (10)

Country Link
US (1) US20230293495A1 (es)
EP (1) EP4221704B1 (es)
JP (1) JP2023544327A (es)
KR (1) KR20230079151A (es)
CN (1) CN116367831A (es)
AU (1) AU2021351536A1 (es)
BR (1) BR112023005987A2 (es)
CA (1) CA3193661A1 (es)
MX (1) MX2023003783A (es)
WO (1) WO2022072811A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119497613A (zh) 2022-05-09 2025-02-21 奥莱松基因组股份有限公司 使用lsd1抑制剂治疗nf1-突变肿瘤的方法
JP2025516647A (ja) 2022-05-09 2025-05-30 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｌｓｄ１阻害薬を用いる悪性末梢神経鞘腫（ｍｐｎｓｔ）の治療法
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
US20060089387A1 (en) * 2004-10-26 2006-04-27 Le Huang Stabilized pharmaceutical composition comprising antidiabetic agent
UA103332C2 (ru) * 2008-07-28 2013-10-10 Такеда Фармасьютикал Компани Лимитед Фармацевтическая композиция, которая содержит непептидный активный агент с первичной или вторичной аминогруппой
WO2010113840A1 (ja) * 2009-03-30 2010-10-07 アステラス製薬株式会社 ソリフェナシン非晶質体を含有した固形医薬組成物
CN105142615A (zh) * 2011-09-14 2015-12-09 细胞基因公司 环丙烷羧酸{2-[(1s)-1-(3-乙氧基-4-甲氧基-苯基)-2-甲烷磺酰基-乙基]-3-氧代-2,3-二氢-1h-异吲哚-4-基}-酰胺的制剂细胞基因公司公司设立的州：特拉华州
WO2015170237A1 (en) * 2014-05-05 2015-11-12 Torrent Pharmaceuticals Limited Stable solifenacin composition
PT3256218T (pt) * 2015-02-12 2025-01-29 Imago Biosciences Inc Um inibidor de kdm1a e a sua utilização na terapia
US20190070172A1 (en) * 2015-11-05 2019-03-07 Imago Biosciences, Inc. Lysine-specific histone demethylase as a novel therapeutic target in myeloproliferative neoplasms
CR20180553A (es) * 2016-04-22 2019-02-01 Incyte Corp Formulaciones de un inhibidor de lsd1
US11390590B2 (en) * 2016-08-16 2022-07-19 Imago Biosciences, Inc. Methods and processes for the preparation of KDM1A inhibitors
CN115397820A (zh) * 2019-12-09 2022-11-25 伊美格生物科学公司 用于治疗骨髓增生性肿瘤的赖氨酸特异性组蛋白脱甲基化酶抑制剂

Also Published As

Publication number Publication date
WO2022072811A1 (en) 2022-04-07
JP2023544327A (ja) 2023-10-23
CN116367831A (zh) 2023-06-30
US20230293495A1 (en) 2023-09-21
EP4221704A4 (en) 2024-11-06
KR20230079151A (ko) 2023-06-05
AU2021351536A1 (en) 2023-05-04
CA3193661A1 (en) 2022-04-07
EP4221704B1 (en) 2025-09-24
EP4221704A1 (en) 2023-08-09
BR112023005987A2 (pt) 2023-05-02

Similar Documents

Publication Publication Date Title
MX2023003783A (es) Formulaciones farmaceuticas para tratar enfermedades mediadas por kdm1a.
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
WO2021021979A3 (en) Hdac6 inhibitors and uses thereof
MX2023005984A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
GEP20237568B (en) 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
MX2023005983A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
PH12021551792A1 (en) Bi-ligand drug conjugate and use thereof
ZA202403388B (en) Small molecules for treatement of cancer
MX2022005809A (es) Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente del regulador de la conductancia a nivel transmembranario de la fibrosis quistica (cftr).
CY1116215T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
MX2017010287A (es) Composiciones farmaceuticas que comprenden n-(3,5-dimetoxifenil)-n '-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il)quinoxalin-6-il]eta no-1,2-diamina.
CA2777746A1 (en) Benzoimidazole compounds and uses thereof
EP4306523A3 (en) Imidazoquinoline compounds and uses thereof
CL2024003232A1 (es) Compuestos derivados de heteroarilo y uso para tratar el dolor.
BR112015030578A2 (pt) combinações farmacêuticas
CL2024003231A1 (es) Compuestos derivados de heteroarilo y uso para tratar el dolor.
CR20210043A (es) Forma de dosificación farmacèutica administrable por vía oral con liberación modificada
MX2024009444A (es) Métodos de tratamiento para la fibrosis quística
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
MX2024014315A (es) Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas
GB2590189A9 (en) Lycorine derivatives, pharmaceutical composite thereof and usage therefor
AR039895A1 (es) Composicion que comprende una vitamina, una sal de metal y una insulina o una hormona del crecimiento y uso de dichos componentes para prepararla
AR127966A1 (es) Formulaciones tópicas de inhibidores de pi3k-delta
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.